Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Country-specific medical scientific information for Healthcare Professionals.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Boehringer Ingelheim are taking on cancer through a dedicated commitment to delivering first-in-class cancer-cell directed therapies, innovative immuno-oncology strategies and smart combination approaches. Our goal is to achieve cancer breakthroughs that give hope to patients. Find out more about our oncology clinical trial programme and long-term research commitment below.
| LATEST DEVELOPMENT PHASE | ||||
|---|---|---|---|---|
| Compound and target | Phase I | Phase II | Phase III | Approved |
|
Afatinib |
NSCLC
A
Approved
|
|||
|
Nintedanib |
NSCLC
A
Approved
|
|||
|
Xentuzumab (BI 836845) |
NSCLC
1
Phase I
Breast cancer
1
Phase I
|
Breast cancer
2
Phase II
|
||
|
CD33 monoclonal antibody (BI 836858) |
AML
1
Phase I
|
AML
2
Phase II
|
||
|
PD-1 inhibitor (BI 754091) |
Solid tumours
1
Phase I
|
Solid tumours
2
Phase II
|
||
|
LAG-3 inhibitor (BI 754111) |
Solid tumours
1
Phase I
|
Solid tumours
2
Phase II
|
||
|
VEGF/Ang2 inhibitor (BI 836880) |
Solid tumours
1
Phase I
|
|||
|
BET inhibitor (BI 894999) |
Solid tumours
1
Phase I
|
|||
|
SMAC mimetic (BI 891065) |
Solid tumours
1
Phase I
|
|||
|
MDM2-p53 antagonist (BI 907828) |
Solid tumours
1
Phase I
|
|||
|
LRP5/6 antagonist (BI 905677) |
Solid tumours
1
Phase I
|
|||
|
SIRPα antagonist (BI 765063) |
Solid tumours
1
Phase I
|
|||
|
mRNA-based cancer vaccine (BI 1361849) |
NSCLC
1
Phase I
|
|||
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information..
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here.
Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063 and BI 1361849 are investigational compounds and have not been approved. Their safety and efficacy have not been established.
Ang-2, angiopoietin-2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; LAG3, lymphocyte activation gene 3 protein; MAGE, melanoma-associated antigen; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; MUC1, mucin 1; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death protein 1; PDGFR, platelet-derived growth factor receptor; SMAC, second mitochondria-derived activator of caspase; TPBG, trophoblast glycoprotein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: May 2019
Prescribing Information: GIOTRIF®. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf (Accessed: April 2019)
Prescribing Information: VARGATEF®. https://www.ema.europa.eu/en/documents/product-information/vargatef-epar-product-information_en.pdf (Accessed: April 2019)
ClinicalTrials.gov. NCT03099174. https://clinicaltrials.gov/ct2/show/NCT03099174 (Accessed: April 2019)
ClinicalTrials.gov. NCT02123823. https://clinicaltrials.gov/ct2/show/NCT02123823 (Accessed: April 2019)
ClinicalTrials.gov. NCT03659136. https://clinicaltrials.gov/ct2/show/NCT03659136 (Accessed: April 2019)
ClinicalTrials.gov. NCT03207191. https://clinicaltrials.gov/ct2/show/NCT03207191 (Accessed: April 2019)
ClinicalTrials.gov. NCT02632721. https://clinicaltrials.gov/ct2/show/NCT02632721 (Accessed: April 2019)
ClinicalTrials.gov. NCT03013998. https://clinicaltrials.gov/ct2/show/NCT03013998 (Accessed: April 2019)
ClinicalTrials.gov. NCT03468426. https://clinicaltrials.gov/ct2/show/NCT03468426 (Accessed: April 2019)
ClinicalTrials.gov. NCT02952248. https://clinicaltrials.gov/ct2/show/NCT02952248(Accessed: April 2019)
ClinicalTrials.gov. NCT03156114. https://clinicaltrials.gov/ct2/show/NCT03156114 (Accessed: April 2019)
ClinicalTrials.gov. NCT03780725. https://clinicaltrials.gov/ct2/show/NCT03780725 (Accessed: April 2019)
ClinicalTrials.gov. NCT03433898. https://clinicaltrials.gov/ct2/show/NCT03433898 (Accessed: April 2019)
ClinicalTrials.gov. NCT03166631. https://clinicaltrials.gov/ct2/show/NCT03166631 (Accessed: April 2019)
ClinicalTrials.gov. NCT03697304. https://clinicaltrials.gov/ct2/show/NCT03697304 (Accessed: April 2019)
ClinicalTrials.gov. NCT02674152. https://clinicaltrials.gov/ct2/show/NCT02674152 (Accessed: April 2019)
ClinicalTrials.gov. NCT02689505. https://clinicaltrials.gov/ct2/show/NCT02689505 (Accessed: April 2019)
ClinicalTrials.gov. NCT02516553. https://clinicaltrials.gov/ct2/show/NCT02516553 (Accessed: April 2019)
ClinicalTrials.gov. NCT03449381. https://clinicaltrials.gov/ct2/show/NCT03449381 (Accessed: April 2019)
ClinicalTrials.gov. NCT03604445. https://clinicaltrials.gov/ct2/show/NCT03604445 (Accessed: April 2019)
ClinicalTrials.gov. NCT03164772. https://clinicaltrials.gov/ct2/show/NCT03164772 (Accessed: April 2019)